摘要
【目的】采用Meta分析评价联用曲美他嗪（TMZ）治疗酒精性心肌病（ACM ）的有效性。【方法】检索PubMed、MedLine、Clinical Trials、Cochrane临床对照试验中心数据库、CNKI全文数据库、万方医学数据库、维普全文数据库建库至今公开发表的与TMZ治疗ACM 相关的临床试验文献。按照纳入和排除原则进行文献筛选及进行方法学质量评估。采用RevM an 5．2软件进行M eta分析。【结果】共纳入5项研究，288例患者。Meta分析显示：与β受体阻滞剂、血管紧张素转换酶抑制剂（ACEI）、利尿剂、维生素等常规治疗相比，联用TMZ治疗可明显增加6分钟步行距离（WMD＝74．53，95％ CI 25．55～123．50），明显提高左室射血分数（W M D＝5．15，95％ C I 2．82～7．49），具有更好的治疗有效性（O R＝8．94，95％ C I 2．44～32．80）。【结论】联用TMZ可明显改善ACM患者的心功能指标，改善患者生活质量。
[Objective] To evaluate the effectiveness of trimetazidine（TMZ） for the combined treatment of alcoholic cardiomyopathy（ACM） by using Meta‐analysis .[Methods] The published clinical trial articles about TMZ for the treatment of ACM by searching the databases of PubMed ,MedLine ,Clinical Trials ,Cochrane Library ,CNKI ,Wangfang and Weipu .According to enrollment and exclusion principle ,the articles were screened and evaluated by methodological quality assessment .Meta‐analysis was accomplished by RevMan 5 .2 software .[Results] Totally 5 studies（288 patients） were enrolled .Meta‐analysis showed that the combined treatment with TMZ could obviously increase the distance of 6‐minute walk test （6MWT ）[weighted mean difference（WMD）=74 .53 ,95% confidence interval（CI） 25 .55 to 123 .50] ,and improve left ventricular ejec‐tion fraction（LVEF）（WMD=5 .15% ,95% CI 2 .82 to 7 .49） ,and had better treatment effectiveness [odds ra‐tio（OR）=8 .94 ,95% CI 2 .44 to 32 .80] in comparison with the convention therapy with beta‐receptor bloc‐ker ,angiotensin converting enzyme inhibitor （ACEI） ,diuretics and vitamins .[Conclusion] The combined treatment with TMZ can obviously improve cardiac function indicators of ACM patients with ACM ,and en‐hance the quality of life .
出处
《医学临床研究》
CAS
2014年第10期1925-1928,共4页
Journal of Clinical Research
